Another deputy general manager of Hengrui resigned, less than 8 months into office

【Pharmaceutical Network Enterprise News】Since the beginning of this year, Hengrui Pharmaceutical's personnel changes have been frequent
.
The company announced on the evening of December 4 that Zhang Xiaojing, deputy general manager and chief medical officer (oncology) of the company, resigned
due to personal reasons.
According to the data, Zhang Xiaojing has worked in multinational pharmaceutical companies such as Novartis Pharma and Bayer, and joined Hengrui Pharmaceutical in 2019 as the deputy general manager of the subsidiary, in charge of the clinical research and development oncology department, responsible for the clinical development of innovative oncology drugs and the research of unmarketed new drugs, and was promoted to the deputy general manager of Hengrui on April 13, 2022, and the time
from his appointment to his departure was less than 8 months.
In addition to Zhang Xiaojing, Hengrui also had 3 deputy general managers resign during
the year.
On October 10, Hengrui Pharmaceutical announced that Tao Weikang, deputy general manager of the company, resigned
due to personal reasons.
According to the 2021 annual report, Tao Weikang's total pre-tax compensation for the whole year of 2021 was 4.
8438 million yuan
.
Tao Weikang has been working for Hengrui Pharmaceutical for nearly 8 years, serving as the company's deputy general manager and CEO
of the R&D center.
Previously, Tao Weikang also engaged in the research and development of new drugs at Merck for many years, and presided over the research and development
of a number of new anti-tumor drugs.
On April 12, Hengrui Pharmaceutical announced that Zou Jianjun, deputy general manager of the company who is also the chief medical officer, resigned
.
Previously, Zou Jianjun worked at Bayer in Germany and Celgene Pharma in the United States, responsible for medical affairs related positions; He joined Hengrui Pharmaceutical in 2015 and served as Chief Medical Officer and Deputy General Manager
.
On February 25, Hengrui Pharmaceutical issued an announcement that Zhang Yuehong, deputy general manager, submitted a resignation report
.
It is reported that Ms.
Zhang Yuehong joined Hengrui Pharmaceutical as the chief human resources officer in December 2018, and previously held human resources related positions
at Novartis.
Of course, there are departures and new executives
.
Not long ago, Hengrui announced the appointment of Dr.
Shi Wei, Dr.
Zhu Xiaoyu and Dr.
Wang Linna as the deputy general managers of the clinical R&D department, respectively serving as the chief medical officer (CMO) of clinical research of chest, breast tumors and gastrointestinal tumors, and reported
to Wang Quanren, deputy general manager of the company in charge of the clinical R&D department.
In this regard, the company believes that this will help the company to further inject "new blood"
on the basis of ensuring the continuity and stability of innovation and research and development.
At the same time, it is also a further optimization of the innovative R&D architecture, which is conducive to improving the efficiency of clinical development and accelerating the company's new drug research and development
.
Judging from the whereabouts of Hengrui's departing executives, many of them have flowed to pharmaceutical companies
that are in competition with Hengrui.
For example, Xiaojing Zhang, who just announced her departure from Hengrui, will join Antengene as the company's Chief Medical Officer (CMO), reporting directly to the company's founder, chairman and CEO, Dr
.
Jianming Mei.
Xiaojing Zhang will be responsible for Antengene's global clinical development strategy and medical team development, based in Shanghai and New Jersey
.
Antengene is an innovative biopharmaceutical company
dedicated to the commercialization phase of R&D, production and marketing of first-in-class and/or best-in-class hematological and solid tumor therapies.
Since 2017, the company has built an increasingly rich pipeline and currently has 15 clinical and preclinical products, of which 10 products have global rights and 5 products have interests in the Asia-Pacific market
, including Greater China.
To date, Antengene has obtained 24 clinical approvals (INDs) in the United States and Asia, and submitted 6 new drug applications (NDAs)
in several Asia-Pacific regions.
XPOVIO (Celinisol) has received new drug marketing approval
from Chinese mainland, Taiwan, South Korea, Singapore and Australia.
For another example, Tao Weikang, who was formerly the deputy general manager and CEO of Hengrui R&D, joined Qilu Pharmaceutical as the vice president of the group and the general manager of Qilu Global Innovative Drug R&D; Jianjun Zou joined Junshi Biologics as the company's deputy general manager and global R&D president, responsible for the company's global research and development work
.
In general, under the background of the normalization of centralized procurement and medical insurance fee control, the flow of talents in the entire pharmaceutical market, especially the innovative drug market, is accelerating, and a new round of man-grabbing war has begun
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.